==Origin and development== Bortezomib was originally synthesized in 1995 at Myogenics. The drug (PS-341) was tested in a small Phase I clinical trial on patients with Multiple Myeloma. It was brought to further clinical trials by Millennium Pharmaceuticals in October 1999. In May 2003, seven years after the initial synthesis, Bortezomib (marketed ...
Found on
http://en.wikipedia.org/wiki/Bortezomib
A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor...
Found on
http://www.cancer.gov/dictionary?expand=B
No exact match found.
